Current treatment options have improved survival rates but have not provided a cure. Eventually, initial therapies stop ...

ASCO Data Shows New Therapy Keeps Myeloma Patients in Remission for 5+ Years. Here's what you need to know about the ...

Results from the Phase Ib/II CARTITUDE-1 trial demonstrated that a single infusion of Carvykti delivered durable, ...

In An Exercise in Uncertainty, Jon Gluck traces decades of waiting, watching, enduring experimental treatment, and ...

A retrospective, real-world data analysis from the TriNetX database sought to determine rates of venous thromboembolism and survival outcomes in patients with multiple myeloma who were treated with ...

Multiple myeloma is considered incurable, but a third of patients in a clinical trial have lived without detectable cancer for years, after facing certain death ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

At 38, author Jonathan Gluck was diagnosed with blood cancer and given less than three years to live. He's written a memoir ...

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content ...